Division of Pediatric Rheumatology, Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Bronx, NY, USA.
Children's Hospital Los Angeles, Los Angeles, CA, USA.
Pediatr Rheumatol Online J. 2023 Sep 12;21(1):100. doi: 10.1186/s12969-023-00873-0.
Throughout the COVID-19 pandemic, there have been concerns regarding the risks of infection in patients with autoimmune disease. In this study, we investigated the impact of the pandemic on patients with juvenile idiopathic inflammatory myopathies (JIIM).
Data were collected using a patient/caregiver survey via Research Electronic Data Capture (REDCap) database. Eligibility included JIIM diagnosis and current age less than 21 years old. Surveys were distributed via the CureJM organization, social media, Childhood Arthritis and Rheumatology Research Alliance (CARRA) network and Dr. Peter Dent Pediatric Rheumatology Bulletin Board.
Eighty-four respondents accessed the survey, 70 (83%) consented to participate, and 54 out of 70 completed the full survey (77%). Twenty-seven out of 57 patients (47%) tested positive for COVID-19, with 7 (12%) testing positive more than once. Despite broad usage of immunosuppressive medications, 24 out of 27 (89%) reported mild symptoms with none requiring hospitalization. Four patients reported a flare of JIIM symptoms after COVID-19; three of whom held immunomodulatory medications during their infection. Thirty-seven out of 54 respondents (69%) reported vaccination against COVID-19, with 9 out of 37 (24%) reporting minor vaccine side effects and one reporting JIIM flare post vaccination. Twenty-one out of 54 (39%) respondents reported psychosocial concerns related to the COVID-19 pandemic.
Patients with JIIM, including those on multiple immunosuppressive medications, had mild symptoms related to COVID-19. Most patients tolerated COVID-19 vaccination well. Few patients had disease flare post-COVID-19 or vaccination. Mental health concerns were demonstrated in JIIM patients during the COVID-19 pandemic.
在整个 COVID-19 大流行期间，人们一直担心自身免疫性疾病患者的感染风险。在这项研究中，我们调查了大流行对幼年特发性炎性肌病（JIIM）患者的影响。
使用 Research Electronic Data Capture（REDCap）数据库通过患者/护理人员调查收集数据。合格标准包括 JIIM 诊断和当前年龄小于 21 岁。通过 CureJM 组织、社交媒体、儿童关节炎和风湿病研究联盟（CARRA）网络以及 Peter Dent 博士儿科风湿病公告板分发调查。
84 名受访者访问了该调查，70 名（83%）同意参与，70 名中有 54 名完成了完整的调查（77%）。57 名患者中有 27 名（47%） COVID-19 检测呈阳性，其中 7 名（12%）检测呈阳性超过一次。尽管广泛使用免疫抑制药物，27 名患者中有 24 名（89%）报告症状轻微，无一人需要住院治疗。4 名患者在 COVID-19 后报告 JIIM 症状发作；其中 3 人在感染期间使用免疫调节剂药物。54 名受访者中有 37 名（69%）报告接种 COVID-19 疫苗，其中 9 名（24%）报告轻微疫苗副作用，1 名报告接种后 JIIM 发作。54 名受访者中有 21 名（39%）报告与 COVID-19 大流行相关的心理社会问题。
患有 JIIM 的患者，包括那些使用多种免疫抑制剂药物的患者，与 COVID-19 相关的症状轻微。大多数患者对 COVID-19 疫苗接种耐受良好。少数患者在 COVID-19 后或接种疫苗后出现疾病发作。在 COVID-19 大流行期间，JIIM 患者表现出心理健康问题。
